Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases ...

The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target of $138.00. The company’s shares closed yesterday ...

Moreover, Biogen’s valuation appears to be fairly priced at current levels, as indicated by a Discounted Cash Flow analysis projecting revenues through 2033. While the company has potential ...

Biogen Inc. (NASDAQ:BIIB), a leader in biotechnology, announced the appointment of Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller, effective March 1, 2025 ...

As the new year unfolds, Napa residents can look forward to the latest installment of the Green Screen Film Series, a line-up of short, pithy films about important environmental topics with some ...

FNAF Gregory is one of the more important human characters in this lore-rich survival horror series, and the mysteries that surround him are some of the most intriguing story elements in recent years.

Biogen's stock underperformed in 2024 due to poor sales of Leqembi and declining multiple sclerosis revenues, despite efforts to diversify its pipeline. Leqembi's market struggles continue, with ...

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company's challenges in establishing its presence in the market for Alzheimer ...

Ginger-flavored beverages are barroom staples, the indispensable spicy-sweet partner to some of your favorite drinks. A Dark 'n Stormy and various Mules and Bucks wouldn’t be complete without ...